Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 6Phase 1 4Phase EARLY_PHASE1 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 9Squamous Cell Carcinoma of Head and Neck 3Skin Neoplasms 3Sarcoma 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Sarcoma, Kaposi 1Pinealoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Muscle Invasive Bladder Urothelial Carcinoma 1Motor Activity 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lymphoid Interstitial Pneumonia 1Liver Neoplasms 1Laryngeal Diseases 1Hodgkin Disease 1Glioma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoma, Basal Cell 1Borderline Resectable Pancreatic Adenocarcinoma 1Acquired Immunodeficiency Syndrome 1

Interventions

pembrolizumab 1cemiplimab 1avelumab 1Nivolumab 1Ipilimumab 1Immune Checkpoint Inhibitors 1Exercise 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Merkel Cell × Nivolumab × Clear all
NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡